Biophytis has enrolled and treated the first patient in its SARA-INT trial, a Phase IIb clinical study of Sarconeos for treatment of sarcopenia.

As part of the double-blind, placebo-controlled trial, approximately 334 patients will be enrolled in 22 clinical centres in Belgium, France, Italy and the US.

The trial will include nearly half of its patients from an observational study, SARA-OBS, which has been conducted by Biophytis at some of the key clinical centres over the past year.

Remaining patients will be enrolled from 11 new clinical centres, which are in the process of opening.

With patient enrolment due for completion by the year-end, the trial plans to release preliminary and final results next year.

“The study’s main evaluation criteria includes walking speed measured during a 400m test.”

The study seeks to examine the safety and efficacy of two doses of BIO101 that will be administered orally for 26 weeks against placebo in a population of men and women aged 65 years and older.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

It also aims to determine the effect of treatment, improvement of physical function, and decreased risk of motor disability after six months of treatment with placebo.

In addition, the study’s main evaluation criteria includes walking speed measured during a 400m test.

Its main secondary endpoints are the variation from baseline of standard patient-reported outcome (PRO): PF-10 score of SF36; chair-lift test (SPPB intermediate score).

Other secondary evaluation criteria of the trial are the change in baseline of appendix body mass (ALM), body composition measured by DEXA, muscle strength (handle / knee extension); climb test of the stairs; SPPB; six-minute walk.